Results 21 to 30 of about 71,560 (137)

Expression of Glucagon-Like Peptide 1 Receptor during Osteogenic Differentiation of Adipose-Derived Stem Cells [PDF]

open access: yesEndocrinology and Metabolism, 2014
BackgroundGlucagon-like peptide 1 (GLP-1), an incretin hormone well known for its glucose-lowering effect, was recently reported to exert an anabolic effect on bone. Although the exact mechanism is not known, it likely involves the GLP-1 receptor (GLP-1R)
Yun Kyung Jeon   +10 more
doaj   +1 more source

How glucagon-like peptide 1 receptor agonists work

open access: yesEndocrine Connections, 2021
In recent years, glucagon-like peptide 1 receptor agonists (GLP-1RAs) have become central in the treatment of type 2 diabetes (T2D). In addition to their glucose-lowering properties with low risk of hypoglycaemia, GLP-1RAs reduce body weight and show ...
Christine Rode Andreasen   +3 more
doaj   +1 more source

The therapeutic potential of glucagon-like peptide-1 receptor analogs for neuroinflammation in the setting of asthma [PDF]

open access: yesExploration of Asthma & Allergy
Glucagon-like peptide-1 (GLP-1) is a hormone that regulates blood glucose levels and is produced by the enteroendocrine glands in the large and small intestines in response to the consumption of foods that contain carbohydrates, fats, and proteins.
Courtney Lehman, Ray Stokes Peebles Jr
doaj   +1 more source

Effects of GLP-1 Receptor Polymorphisms on Adolescent Obesity

open access: yesActa Medica Iranica, 2023
Obesity is becoming a concerning disease in developing countries. Like other multifactorial diseases, genetics plays a substantial role in the development of this disease. We tried to investigate genetic variations (mutation/polymorphism) of GLP-1R gene
Mahafarin Maralani   +8 more
doaj   +1 more source

Glucagon-like peptide-1, glucagon-like peptide-2, and lipid metabolism [PDF]

open access: yesCurrent Opinion in Lipidology, 2016
Glucagon-like peptide-1 (GLP-1) is the best known incretin hormone able to potentiate glucose-induced insulin secretion. Moreover, GLP-1 is currently under intensive investigation as a potential crucial mediator of beneficial metabolic effects after bariatric surgery, because of its eating inhibitory, antiobesity, and antidiabetes effects.
Thomas A. Lutz, Elena Osto
openaire   +2 more sources

The associations of incretin hormone concentration with gestational diabetes mellitus

open access: yesСахарный диабет, 2016
Background: Enteropancreatic hormonal system disorder is a possible reason for β-cell dysfunction and carbohydrate metabolism disorder among pregnant women. However, no information is available about the state of enteroinsulin hormones [glucagon, glucose-
Tatiana V. Saprina   +7 more
doaj   +1 more source

GRK Inhibition Potentiates Glucagon-Like Peptide-1 Action

open access: yesFrontiers in Endocrinology, 2021
The glucagon-like peptide-1 receptor (GLP-1R) is a G-protein-coupled receptor (GPCR) whose activation results in suppression of food intake and improvement of glucose metabolism. Several receptor interacting proteins regulate the signaling of GLP-1R such
Seunghun P. Lee   +7 more
doaj   +1 more source

New perspectives on the use of glucagon-like peptide 1 in diseases of the central nervous system

open access: yesCurrent Issues in Pharmacy and Medical Sciences, 2023
Glucagon-like peptide 1 is a neuromodulatory peptide that regulates the carbohydrate metabolism. It can cross the blood-brain barrier, and, indeed, while mostly produced in the distal small intestine and colon, it is also synthesized in the nucleus of ...
Lupina Malgorzata, Listos Joanna
doaj   +1 more source

Glucagon-Like Peptide-1 and Diabetes [PDF]

open access: yesExperimental Diabetes Research, 2011
This special issue was focused on the role and the effects of glucagon-like peptide-1 (GLP-1) in type 2 diabetes. This gastrointestinal hormone, which is mainly secreted after meals, enhances glucose-stimulated insulin release and inhibits food intake.
openaire   +2 more sources

Glucagon‐like peptide‐1 receptor agonists and kidney outcomes

open access: yesJournal of Diabetes
Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have gained increasing attention for their potential benefits in people with type 2 diabetes mellitus (T2DM) with chronic kidney disease (CKD). Most supportive evidence of a kidney‐protective effect of
Richard J. MacIsaac   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy